PL1663320T3 - Celowane niszczenie unaczynienia guza przy pomocy znakowanego radioaktywnie przeciwciała l19 przeciw fibronektynie ED-B - Google Patents

Celowane niszczenie unaczynienia guza przy pomocy znakowanego radioaktywnie przeciwciała l19 przeciw fibronektynie ED-B

Info

Publication number
PL1663320T3
PL1663320T3 PL04764695T PL04764695T PL1663320T3 PL 1663320 T3 PL1663320 T3 PL 1663320T3 PL 04764695 T PL04764695 T PL 04764695T PL 04764695 T PL04764695 T PL 04764695T PL 1663320 T3 PL1663320 T3 PL 1663320T3
Authority
PL
Poland
Prior art keywords
domain
antibody
cdr1
cdr2
seq
Prior art date
Application number
PL04764695T
Other languages
English (en)
Inventor
Laura Borsi
B Carnemolla
Enrica Balza
P Castellani
L Zardi
Matthias Friebe
Christoph-Stephan Hilger
Original Assignee
Philogen Spa
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa, Bayer Schering Pharma Ag filed Critical Philogen Spa
Publication of PL1663320T3 publication Critical patent/PL1663320T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL04764695T 2003-09-10 2004-09-01 Celowane niszczenie unaczynienia guza przy pomocy znakowanego radioaktywnie przeciwciała l19 przeciw fibronektynie ED-B PL1663320T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50188103P 2003-09-10 2003-09-10
EP03255633A EP1514561A1 (en) 2003-09-10 2003-09-10 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
EP04764695A EP1663320B1 (en) 2003-09-10 2004-09-01 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b
PCT/EP2004/009733 WO2005023318A1 (en) 2003-09-10 2004-09-01 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b

Publications (1)

Publication Number Publication Date
PL1663320T3 true PL1663320T3 (pl) 2011-07-29

Family

ID=34130349

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04764695T PL1663320T3 (pl) 2003-09-10 2004-09-01 Celowane niszczenie unaczynienia guza przy pomocy znakowanego radioaktywnie przeciwciała l19 przeciw fibronektynie ED-B

Country Status (27)

Country Link
US (2) US20050074401A1 (pl)
EP (3) EP1514561A1 (pl)
JP (1) JP2007505065A (pl)
KR (1) KR101129161B1 (pl)
CN (1) CN100482285C (pl)
AT (1) ATE499949T1 (pl)
AU (2) AU2004269897B2 (pl)
BR (1) BRPI0414272A (pl)
CA (1) CA2536256C (pl)
CR (2) CR8331A (pl)
DE (1) DE602004031635D1 (pl)
DK (1) DK1663320T3 (pl)
EA (1) EA010653B1 (pl)
EC (1) ECSP066499A (pl)
ES (1) ES2361743T3 (pl)
IL (1) IL173560A0 (pl)
ME (1) MEP13108A (pl)
NO (1) NO20061619L (pl)
NZ (1) NZ545640A (pl)
PL (1) PL1663320T3 (pl)
PT (1) PT1663320E (pl)
RS (1) RS20060176A (pl)
SG (1) SG162760A1 (pl)
SI (1) SI1663320T1 (pl)
UA (1) UA89759C2 (pl)
WO (1) WO2005023318A1 (pl)
ZA (1) ZA200602014B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
EP2174958A1 (en) * 2002-03-11 2010-04-14 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
CN104395342B (zh) * 2013-06-06 2017-07-04 合肥立方制药股份有限公司 人源抗纤连蛋白ed‑b结构域的抗体及其用途
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP7352040B2 (ja) 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
JP7690131B2 (ja) 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
CN119775344B (zh) * 2024-12-31 2025-08-26 英科新创（苏州）生物科技有限公司 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
EP2174958A1 (en) * 2002-03-11 2010-04-14 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature

Also Published As

Publication number Publication date
NO20061619L (no) 2006-04-10
HK1092375A1 (zh) 2007-02-09
NZ545640A (en) 2009-05-31
ZA200602014B (en) 2007-05-30
US20050074401A1 (en) 2005-04-07
CR20110168A (es) 2011-06-03
SG162760A1 (en) 2010-07-29
WO2005023318A1 (en) 2005-03-17
US20090214423A1 (en) 2009-08-27
MEP13108A (en) 2011-05-10
IL173560A0 (en) 2006-07-05
AU2010200271A1 (en) 2010-02-18
EA010653B1 (ru) 2008-10-30
DK1663320T3 (da) 2011-06-06
EP1663320B1 (en) 2011-03-02
CA2536256C (en) 2013-02-26
UA89759C2 (ru) 2010-03-10
CR8331A (es) 2006-10-04
ECSP066499A (es) 2006-10-10
CN1849144A (zh) 2006-10-18
AU2004269897B2 (en) 2009-11-05
CA2536256A1 (en) 2005-03-17
EA200600494A1 (ru) 2006-08-25
EP2246070A2 (en) 2010-11-03
DE602004031635D1 (de) 2011-04-14
JP2007505065A (ja) 2007-03-08
CN100482285C (zh) 2009-04-29
ATE499949T1 (de) 2011-03-15
RS20060176A (sr) 2008-08-07
KR101129161B1 (ko) 2012-03-28
EP1663320A1 (en) 2006-06-07
AU2004269897A1 (en) 2005-03-17
ES2361743T3 (es) 2011-06-21
SI1663320T1 (sl) 2011-06-30
EP1514561A1 (en) 2005-03-16
BRPI0414272A (pt) 2006-11-07
KR20060118430A (ko) 2006-11-23
PT1663320E (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
CR20110168A (es) Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-b de fibronectina marcado radioactivamente (divisional solicitud 8331)
Tang et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
AU2003219370B2 (en) Antibodies derived rom anti ED-B L19 and targeting tumor vasculature
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
MX2023004434A (es) Anticuerpos anti-fgfr2 y metodos para usarlos.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
PE20020871A1 (es) Moleculas de enlace terapeuticas
HRP20160270T1 (hr) Monoklonska antitijela protiv glipikana-3
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
PT1299421E (pt) Anticorpos para a mcp-1 humana
WO2005026210A3 (en) Therapeutic binding molecules
Karacay et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
Sharkey et al. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting
Corneillie et al. Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting
JP2007508352A5 (pl)
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека
Pimm et al. Influence of a syngeneic anti-idiotypic antibody response to a mouse anti-tumour monoclonal antibody on biodistribution of its radiolabelled Fc-intact monovalent Fab/c fragment